Cambrex Corp. (CBM) Trading Down 2.7%
Cambrex Corp. (NYSE:CBM)’s share price dropped 2.7% during mid-day trading on Friday . The company traded as low as $52.18 and last traded at $52.25, with a volume of 411,405 shares traded. The stock had previously closed at $53.72.
Separately, Zacks Investment Research cut shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th.
The company has a market cap of $1.68 billion and a P/E ratio of 26.85. The stock has a 50-day moving average price of $52.73 and a 200-day moving average price of $45.37.
Cambrex Corp. (NYSE:CBM) last issued its earnings results on Thursday, July 28th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.09. The business earned $118.22 million during the quarter, compared to analysts’ expectations of $114.85 million. During the same quarter in the previous year, the business earned $0.63 EPS. Cambrex Corp.’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
In related news, CEO Steven M. Klosk sold 14,005 shares of Cambrex Corp. stock in a transaction on Monday, May 9th. The shares were sold at an average price of $49.00, for a total value of $686,245.00. Following the transaction, the chief executive officer now owns 147,333 shares in the company, valued at approximately $7,219,317. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William B. Korb sold 3,420 shares of Cambrex Corp. stock in a transaction on Monday, July 11th. The stock was sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the transaction, the director now owns 23,982 shares in the company, valued at approximately $1,319,010. The disclosure for this sale can be found here.
Other institutional investors have modified their holdings of the company. California Public Employees Retirement System boosted its position in shares of Cambrex Corp. by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 162,700 shares of the company’s stock worth $7,662,000 after buying an additional 800 shares during the last quarter. Pear Tree Advisors Inc. acquired a new position in shares of Cambrex Corp. during the fourth quarter worth approximately $1,008,000. GSA Capital Partners LLP boosted its position in shares of Cambrex Corp. by 33.2% in the fourth quarter. GSA Capital Partners LLP now owns 26,475 shares of the company’s stock worth $1,247,000 after buying an additional 6,592 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Cambrex Corp. by 2.3% in the fourth quarter. Principal Financial Group Inc. now owns 681,184 shares of the company’s stock worth $32,077,000 after buying an additional 15,623 shares during the last quarter. Finally, Century Capital Management LLC boosted its position in shares of Cambrex Corp. by 13.5% in the fourth quarter. Century Capital Management LLC now owns 353,591 shares of the company’s stock worth $16,651,000 after buying an additional 42,189 shares during the last quarter.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.